George Perry to Drug Design
This is a "connection" page, showing publications George Perry has written about Drug Design.
Connection Strength
0.790
-
Liu G, Men P, Zhu X, Perry G. Iron chelation and nanoparticle target delivery in the development of new multifunctional disease-modifying drugs for Alzheimer's disease. Ther Deliv. 2012 May; 3(5):571-4.
Score: 0.335
-
Elbatrawy AA, Ademoye TA, Alnakhala H, Tripathi A, Plascencia-Villa G, Zhu X, Perry G, Dettmer U, Fortin JS. Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against a-synuclein and 2N4R tau. Bioorg Med Chem. 2024 Dec 15; 116:117990.
Score: 0.200
-
Plascencia-Villa G, Perry G. Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases. Int J Mol Sci. 2023 Aug 06; 24(15).
Score: 0.183
-
Moreira PI, Honda K, Zhu X, Nunomura A, Casadesus G, Smith MA, Perry G. Brain and brawn: parallels in oxidative strength. Neurology. 2006 Jan 24; 66(2 Suppl 1):S97-101.
Score: 0.054
-
Liu G, Men P, Perry G, Smith MA. Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog Brain Res. 2009; 180:97-108.
Score: 0.018